Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).
Sadahiro S, Morita S, Sasaki K, Sakamoto K, Ohge H, Takahashi T, Tsuchiya T, Sato T, Kondo K, Ogata Y, Masuko H, Baba H, Maeda K, Hamada M, Itabashi M, Nishimura G, Takahashi K, Ikeda M, Taguri M, Kodaira S. Sadahiro S, et al. Clin Colorectal Cancer. 2015 Dec;14(4):277-80. doi: 10.1016/j.clcc.2015.05.004. Epub 2015 May 22. Clin Colorectal Cancer. 2015. PMID: 26068602 Free article. Clinical Trial.
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
Sadahiro S, Sakamoto K, Tsuchiya T, Takahashi T, Ohge H, Sato T, Kondo K, Ogata Y, Baba H, Itabashi M, Ikeda M, Hamada M, Maeda K, Masuko H, Takahashi K, Sakamoto J, Kusano M, Hyodo I, Taguri M, Morita S. Sadahiro S, et al. BMC Cancer. 2022 Feb 15;22(1):170. doi: 10.1186/s12885-022-09267-z. BMC Cancer. 2022. PMID: 35168560 Free PMC article. Clinical Trial.
Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Tsuchiya T, Sadahiro S, Sasaki K, Kondo K, Katsumata K, Nishimura G, Kakeji Y, Baba H, Morita T, Koda K, Sato S, Matsuoka J, Yamaguchi Y, Usuki H, Hamada C, Kodaira S, Saji S. Tsuchiya T, et al. Among authors: sadahiro s. Cancer Chemother Pharmacol. 2014 Jun;73(6):1253-61. doi: 10.1007/s00280-014-2461-5. Epub 2014 Apr 18. Cancer Chemother Pharmacol. 2014. PMID: 24744162 Free PMC article. Clinical Trial.
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
Tomita N, Kunieda K, Maeda A, Hamada C, Yamanaka T, Sato T, Yoshida K, Boku N, Nezu R, Yamaguchi S, Mishima H, Sadahiro S, Muro K, Ishiguro M, Sakamoto J, Saji S, Maehara Y. Tomita N, et al. Among authors: sadahiro s. Br J Cancer. 2019 Apr;120(7):689-696. doi: 10.1038/s41416-019-0410-0. Epub 2019 Mar 5. Br J Cancer. 2019. PMID: 30833647 Free PMC article. Clinical Trial.
Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
Sadahiro S, Tsuchiya T, Sasaki K, Kondo K, Katsumata K, Nishimura G, Kakeji Y, Baba H, Sato S, Koda K, Yamaguchi Y, Morita T, Matsuoka J, Usuki H, Hamada C, Kodaira S. Sadahiro S, et al. Ann Oncol. 2015 Nov;26(11):2274-80. doi: 10.1093/annonc/mdv358. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347106 Free PMC article. Clinical Trial.
[Optimal dosage of UFT in a weekday-on/weekend-off schedule as a postoperative adjuvant chemotherapy for colorectal cancer].
Sadahiro S, Ohki S, Yamaguchi S, Takahashi T, Otani Y, Tsukikawa S, Yamamura T, Takemiya S, Nagasaki H, Nishiyama K, Fukushima T, Hiki Y, Yamaguchi S, Kumada K, Shimada H, Mitomi T, Makuuchi H; UFT Compliance Study Group. Sadahiro S, et al. Gan To Kagaku Ryoho. 2000 Dec;27(14):2223-30. Gan To Kagaku Ryoho. 2000. PMID: 11142166 Clinical Trial. Japanese.
Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan.
Sadahiro S, Ohki S, Yamaguchi S, Takahashi T, Otani Y, Tsukikawa S, Yamamura T, Takemiya S, Nagasaki H, Nishiyama K, Fukushima T, Hiki Y, Yamaguchi S, Kumada K, Shimada H, Mitomi T, Makuuchi H. Sadahiro S, et al. Cancer Chemother Pharmacol. 2000;46(3):180-4. doi: 10.1007/s002800000146. Cancer Chemother Pharmacol. 2000. PMID: 11021734 Clinical Trial.
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. Ichikawa W, et al. Among authors: sadahiro s. Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16. Br J Cancer. 2015. PMID: 25880011 Free PMC article.
225 results